Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 5,514Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 13Eliquis

02 2Eliquis

03 1Eliquis Alliance Revenues And Direct Sales

04 1Eliquis alliance revenues and direct sales

PharmaCompass

01

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 9,168

2019 Revenue in Millions : 7,929

Growth (%) : 16

blank

02

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 4,949

2019 Revenue in Millions : 4,220

Growth (%) : 17

blank

03

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 10,762

2020 Revenue in Millions : 9,168

Growth (%) : 17

blank

04

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 5,970

2020 Revenue in Millions : 4,949

Growth (%) : 21

blank

05

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 11,789

2021 Revenue in Millions : 10,762

Growth (%) : 10

blank

06

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 6,480

2021 Revenue in Millions : 5,970

Growth (%) : 9

blank

07

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 12,206

2022 Revenue in Millions : 11,789

Growth (%) : 4

blank

08

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 6,747

2022 Revenue in Millions : 6,480

Growth (%) : 4

blank

09

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Anticoagulants

Currency : USD

2014 Revenue in Millions : 430.10%

2013 Revenue in Millions :

Growth (%) :

blank

10

Brand Name : Eliquis

Apixaban

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Eliquis

arrow
Fi Europe 2024
Not Confirmed

Apixaban

Main Therapeutic Indication : Anticoagulants

Currency : USD

2015 Revenue in Millions : 774

2014 Revenue in Millions : 1,860

Growth (%) : 140%

blank